ERBB2 and breast cancer: In contrast, based on gene expression, the majority of patients (n = 421, ~66%) were identified with estrogen-positive BC, and 28 patients (4.4%) had HER2-positive disease; of these, 9 patient samples (1.4%) were positive for both estrogen and HER2 receptors.